Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer

2002 ◽  
Vol 33 (2) ◽  
pp. 201-205 ◽  
Author(s):  
Jennifer I. Swalwell ◽  
Cathy D. Vocke ◽  
Youfeng Yang ◽  
Jonathan R. Walker ◽  
Lynette Grouse ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Chromosome Band ◽  
Deletion Interval

Determination of Sarcosine Based on Magnetic Cross-linked Enzyme Aggregates for Diagnosis of Prostate Cancer

2021 ◽  
pp. 108039
Author(s):  
Qianqian Hu ◽  
Guoning Chen ◽  
Jili Han ◽  
Lu Wang ◽  
Xia Cui ◽  
...  
Keyword(s):  
Prostate Cancer

scholarly journals Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer

2021 ◽  
Vol 14 (3) ◽  
pp. 188
Author(s):  
Ines Katzschmann ◽  
Heike Marx ◽  
Klaus Kopka ◽  
Ute Hennrich
Keyword(s):  
Prostate Cancer ◽  
Quality Control ◽  
Radiochemical Purity ◽  
Control Method ◽  
Solid Phase ◽  
Hplc Method ◽  
Attractive Alternative ◽  
Chromatography Method ◽  
Pet Tracer

For the PET imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. [18F]PSMA-1007, a radiopharmaceutical labeled with fluorine-18, has excellent properties for the detection of prostate cancer. Essential for the human use of a radiotracer is its production and quality control under GMP-compliance. For this purpose, all analytical methods have to be validated. [18F]PSMA-1007 is easily radiosynthesized in a one-step procedure and isolated using solid phase extraction (SPE) cartridges followed by formulation of a buffered injection solution and for the determination of its chemical and radiochemical purity a robust, fast and reliable quality control method using radio-HPLC is necessary. After development and optimizations overcoming problems in reproducibility, the here described radio-HPLC method fulfills all acceptance criteria—for e.g., specificity, linearity, and accuracy—and is therefore well suited for the routine quality control of [18F]PSMA-1007 before release of the radiopharmaceutical. Recently a European Pharmacopeia monograph for [18F]PSMA-1007 was published suggesting a different radio-HPLC method for the determination of its chemical and radiochemical purity. Since the here described method has certain advantages, not least of all easier technical implementation, it can be an attractive alternative to the monograph method. The here described method was successfully validated on several radio-HPLC systems in our lab and used for the analysis of more than 60 batches of [18F]PSMA-1007. Using this method, the chemical and radiochemical purity of [18F]PSMA-1007 can routinely be evaluated assuring patient safety.

Is the determination of prostatic acid phosphatase still worthwhile in prostate cancer patients?

1997 ◽  
Vol 3 (2) ◽  
pp. 47-50
Author(s):  
Walter L Strohmaier ◽  
Andreas Zumbraegel ◽  
Lennart Koschella ◽  
K Horst Bichler
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Cancer Patients ◽  
Prostatic Acid Phosphatase

TOOKAD®Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer

2013 ◽  
Vol 112 (6) ◽  
pp. 766-774 ◽  
Author(s):  
Abdel-Rahmène Azzouzi ◽  
Eric Barret ◽  
Caroline M. Moore ◽  
Arnaud Villers ◽  
Clare Allen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Optimal Treatment ◽  
Treatment Conditions

Determination of cyclooxygenases and arachidonic acid metabolites in invasive human prostate cancer cells

1999 ◽  
Vol 59 (1-6) ◽  
pp. 13
Author(s):  
Kasem Nithipatikom ◽  
Christine Borcheid ◽  
Andre A. Kajdacsy-Balla ◽  
Sushma Kaul ◽  
Paul F. Lindholm ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Arachidonic Acid ◽  
Cancer Cells ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Arachidonic Acid Metabolites ◽  
Acid Metabolites

scholarly journals American trends in expectant management utilization for prostate cancer from 2000 to 2009

2014 ◽  
Vol 8 (11-12) ◽  
pp. 775 ◽  
Author(s):  
Matthew J. Maurice ◽  
Robert Abouassaly ◽  
Hui Zhu
Keyword(s):  
Prostate Cancer ◽  
Expectant Management ◽  
Patient Characteristics ◽  
Veterans Affairs ◽  
Health Concern ◽  
Teaching Hospitals ◽  
Limited Life ◽  
Appreciable Increase ◽  
Low Volume

Introduction: The overtreatment of early prostate cancer has become a major public health concern. Expectant management (EM) is a strategy to minimize overtreatment, but little is known about its pattern of use. We sought to examine national EM utilization over the preceding decade.Methods: We examined prostate cancer treatment utilization from 2000 to 2009 using the National Cancer Database. EM use was analyzed in relation to other treatments and by cancer stage, age group, Charlson score, and hospital practice setting.Results: Overall, 109 997 (8.2%) men were managed initially with EM. EM usage remained stable at 7.6% to 9.5% from 2000 to 2009 with no appreciable increase for low-stage cancers. Usage was only slightly higher in elderly patients and in patients with multiple comorbidities. Veterans Affairs and low-volume hospitals had a much higher and increasing EM rate (range: 18.8%-29.8% and 15.1%-24.2%, respectively), compared to community hospitals, comprehensive cancer centres, and teaching hospitals, which showed no increased adoption. On further analysis, EM use remained high for low-stage cancers at Veterans Affairs and low-volume hospitals (24.0% and 19.1%, respectively), regardless of age or comorbidity, a pattern not shared by other practice settings.Conclusions: EM utilization remained low and stable last decade, regardless of disease or patient characteristics. Conversely, Veterans Affairs and low-volume hospitals led the trend in national EM adoption, particularly in men with low-stage cancers and limited life expectancies. The limitations of this dataset preclude any determination of the appropriateness of EM utilization. Nonetheless, further study is needed to identify factors influencing EM adoption to ensure its proper use in the future.

scholarly journals Determination of geometrical margins in external beam radiotherapy for prostate cancer: RETRACTION

2019 ◽  
Vol 18 (02) ◽  
pp. 190
Author(s):  
Mohamed Bencheikh ◽  
Abdelmajid Maghnouj ◽  
Jaouad Tajmouati ◽  
Ahmed Dadouch ◽  
Zakariae Benjelloun
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
External Beam
Sign in / Sign up

Export Citation Format

Share Document